Ricerca Biosciences Appoints Eric J. Lubert to Scientific Leadership Role in Biotherapeutics Development

Ricerca Biosciences Appoints Eric J. Lubert to Scientific Leadership Role in Biotherapeutics Development


CONCORD, Ohio--(BUSINESS WIRE)--Oct 7, 2010 - Ricerca Biosciences, a preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the addition of Eric J. Lubert, Ph.D., as a scientist in its drug safety division.

With over ten years of scientific research across a multitude of scientific disciplines, Dr. Lubert will be responsible for the technical management of Ricerca's biotherapeutics assay group and scientific leadership in biotherapeutic development programs. His team will assist with the expansion of Ricerca's current capabilities to provide development services for protein, peptide, siRNA therapeutics, and both prophylactic and therapeutic vaccines.

"Biotherapeutic development continues to be a growth area for the pharmaceutical industry and their CRO partners," observed Dr. Jim Szabo, vice president, drug safety and metabolism. "We're confident Eric will effectively lead Ricerca's expansion of the technical offerings required to fully support the development of biologics."

Prior to joining Ricerca, Dr. Lubert was a research scientist at Battelle Memorial Research Institute where he was responsible for coordinating and advancing select agent detection capabilities. While serving as the research and development manager for Bio-WORLD, he was responsible for supervising business development through expansion of their in-house laboratory capabilities.

Dr. Lubert earned a doctorate in biochemistry from the University of Kentucky in Lexington, Kentucky. He began his post-doctoral training at Nationwide Children's Research Institute in Columbus, Ohio. His research focused on assembling and testing recombinant viral vectors as vaccine candidates against the hepatitis C virus.

Ricerca offers a unique spectrum of services for the areas of preclinical discovery and development for biopharmaceutical registration as well as agrochemical and environmental analyses.

About Ricerca Biosciences

Ricerca Biosciences, LLC, offers a comprehensive suite of discovery, preclinical and development services to support drug candidates from discovery through IND and NDA on a global scale. Capabilities include molecular through in vivo screening and profiling, medicinal chemistry, IND-enabling toxicology, API process chemistry and cGMP manufacturing of clinical and commercial API. At Ricerca, our scientific excellence and reliable, cost-effective strategies help accelerate your drug discovery programs via our U.S. based facilities in Concord, Ohio, and Bothell, Washington, and our ISO 9001-certified facilities in Taipei, Taiwan, and Lyon, France. The Lyon and Bothell facilities also hold AAALAC certification.

 

 

Contact: Ricerca Biosciences, LLC
Heidi Nelson-Keherly, Ph.D.
440-357-3088
[email protected]

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.